Actavis buys UK generics firm for £306m
This article was originally published in Scrip
Executive Summary
Actavis, which will shortly close its $66bn acquisition of Allergan, has agreed to buy privately held UK-focused generics firm Auden Mckenzie for around £306m in cash, plus a two-year royalty on one of Auden Mckenzie's products. The deal promises to make Actavis the number one supplier of generic pharmaceuticals in the UK.